Cornerstones of CRISPR-Cas in drug discovery and therapy.
about
Harnessing public domain data to discover and validate therapeutic targets.How should the applications of genome editing be assessed and regulated?Advances in the delivery of RNA therapeutics: from concept to clinical reality.Targeted protein knockdown using small molecule degraders.Covalent nano delivery systems for selective imaging and treatment of brain tumors.Type II CRISPR/Cas9 approach in the oncological therapy.RNA biology of disease-associated microsatellite repeat expansions.Addressing Pressing Needs in the Development of Advanced Therapies.Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function.Immunity to CRISPR Cas9 and Cas12a therapeutics.CRISPR Genome Engineering for Human Pluripotent Stem Cell Research.Correcting CRISPR for copy number.The Conspicuity of CRISPR-Cpf1 System as a Significant Breakthrough in Genome Editing.Trends in GPCR drug discovery: new agents, targets and indications.Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.CRISPR-Cas9 HDR system enhances AQP1 gene expression.CRISPR/Cas9-mediated noncoding RNA editing in human cancers.Emerging Concepts in Innate Immunity.Standing in the Shifting Sands of Molecular Targeting and Precision Medicine Is the Oasis of 21st-Century Oncology Therapeutics.Modeling Inborn Errors of Hepatic Metabolism Using Induced Pluripotent Stem Cells.Label-Free Dynamic Mass Redistribution and Bio-Impedance Methods for Drug Discovery.CRISPR, Patents, and the Public Health.Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell Type Specific Gene Editing.Tapping the RNA world for therapeutics.CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration.Loss of Zbtb32 in NOD mice does not significantly alter T cell responses.The CRISPR tool kit for genome editing and beyond.Efficient Delivery and Nuclear Uptake Is Not Sufficient to Detect Gene Editing in CD34+ Cells Directed by a Ribonucleoprotein Complex.Cell Line Techniques and Gene Editing Tools for Antibody Production: A Review.CRISPR therapeutic tools for complex genetic disorders and cancer (Review).A splice junction-targeted CRISPR approach (spJCRISPR) reveals human FOXO3B to be a protein-coding geneNeuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer's Disease: Are We There Yet?Extension of the crRNA enhances Cpf1 gene editing in vitro and in vivoThe Interaction of the Gut Microbiota with the Mucus Barrier in Health and Disease in HumanIn vivo CRISPR editing with no detectable genome-wide off-target mutations
P2860
Q30491667-6ECABFB3-AC66-457B-B3CD-FC3155550059Q37737415-E15785EC-F766-47A0-9CD6-0CD5278F820BQ38706445-64697D58-2054-447A-A9FC-2CBB7FF2CB6BQ39367115-B6DBF87E-6886-427C-98C5-333570267F94Q39367664-A0FF3790-4E1B-452D-8FB3-7655777D1692Q39376221-4122D0DE-07BE-4C71-BF69-94C463DFB8D4Q41542861-24E27C3A-A5AA-43BF-8B7F-DCB982C01E0EQ42049796-3CDE874E-4645-40EE-B8D1-E0F8D8AD23B3Q42373442-6AF12335-AB18-401B-86E1-9CCF30382BB5Q45873745-B4F189E3-A688-4374-9E98-6FF1BED6CA58Q46522290-A452BCD7-4E72-4326-9DFF-04E607061D2CQ46776672-B2E7FFCB-BD6C-455E-8191-A44FC46CE161Q47299533-6B22AD88-B0C7-40A0-8877-B27722CEE2D0Q47597808-8AF41AD7-B0D6-41FC-8D25-2CE5F77326B6Q47627028-C51886B6-5302-40DD-9232-A93D2889DAA8Q47713562-B479C3A9-7573-4BBE-A6D6-55EA710B34BBQ48189506-34963672-09BE-407B-BAC7-FF2A17516A57Q49606768-D86B779E-45E6-4E02-846D-DBFFB4526679Q50045474-B9CC5DF3-69EF-4E51-8FF3-B33EDE8D3A13Q50429584-BDE23E5E-C032-4E62-AA73-C90630893199Q50569577-ABA5E924-205B-4E1A-9253-C94F0D596DCDQ52429687-493A242C-EC51-4D0C-B6D2-AF3E48B18119Q52431661-84D2EB1F-02E8-4484-BFF7-0CF0A77059B0Q52584544-6276E967-5657-4844-B048-CF6A3B2CD54AQ54941286-D22F5806-B377-4338-9527-183FC84A520AQ55172689-E6454896-FB77-40C6-87AD-7653E06023A1Q55233775-E7ACC391-BDC2-4836-985E-81C3712F59FEQ55315868-69D82C9A-0FA5-4FEE-BC81-A00959EFCB0EQ55333943-1546B702-17A1-4C11-BA7C-D2D8AEA41D09Q55383943-22247556-CCD3-4AFC-90DD-124EC3E41344Q56980317-7E1260E5-1E86-4058-B933-1C6E0BB84E85Q58727052-A71E3413-D66B-45EF-973C-ECF847E73D78Q58771152-27581597-CE5C-4CC8-BC06-573D7D2199B4Q58802621-39D689F9-3F6C-46DC-B03D-48C813ABF2A2Q59060174-8B048CC6-2290-48F0-BAD3-0B98B4704E75
P2860
Cornerstones of CRISPR-Cas in drug discovery and therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cornerstones of CRISPR-Cas in drug discovery and therapy.
@en
Cornerstones of CRISPR-Cas in drug discovery and therapy.
@nl
type
label
Cornerstones of CRISPR-Cas in drug discovery and therapy.
@en
Cornerstones of CRISPR-Cas in drug discovery and therapy.
@nl
prefLabel
Cornerstones of CRISPR-Cas in drug discovery and therapy.
@en
Cornerstones of CRISPR-Cas in drug discovery and therapy.
@nl
P2093
P2860
P356
P1476
Cornerstones of CRISPR-Cas in drug discovery and therapy.
@en
P2093
Benjamin G Gowen
Jacob E Corn
Pei-Chun Lin
P2860
P2888
P304
P356
10.1038/NRD.2016.238
P577
2016-12-23T00:00:00Z